Immunome Inc (IMNM NASDAQ) stock market data APIs
$15.3852
-0.04(-0.3%)
as of November 7, 2025
Try our APIs with
free plan!
Immunome Inc Financial Data Overview
Price chart is built with
Anychart
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Prev. Close
15.3852
Open
15.3475
High
15.9228
Low
14.5279
52 wk Range
5.1501-17.87
Market Cap
1 398 M
Shares Outstanding
87 045 K
Revenue
12 589 K
EPS
-0.5
Beta
2.191
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunome Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunome Inc data using free add-ons & libraries
Get Immunome Inc Fundamental Data
Immunome Inc Fundamental data includes:
- Net Revenue: 12 589 K
- EBITDA: -188 419 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.6218
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunome Inc News
New
Immunome GAAP EPS of -$0.65
* Immunome press release [https://seekingalpha.com/pr/20297808-immunome-reports-third-quarter-2025-financial-results-and-provides-business-update] (IMNM [https://seekingalpha.com/symbol/IMNM]): Q3 G...
First Week of December 19th Options Trading For Zscaler (ZS)
Investors in Zscaler Inc (Symbol: ZS) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZS option...
Gap downgraded, Ulta upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
OMass Therapeutics PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therape...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
